Actavis Group: A global leader in generic medicines

Actavis Group is a shining star in the global generic drug field. Since its establishment, it has been committed to providing high-quality, cost-effective drug solutions to patients around the world. As a world-class generic drug group headquartered in Switzerland, Actavis occupies a place among the top 50 pharmaceutical companies in the world. Its excellent R&D capabilities and extensive market coverage make it a benchmark company in the industry.

Founded in 1956, Actavis Group has grown into an international pharmaceutical company with a rich product line and strong R&D capabilities after decades of development and accumulation. Today, Actavis is listed on the Swiss Stock Exchange and has won global market recognition for its extensive layout in the fields of central nervous system, digestion, cardiovascular, metabolism, anti-infection, and respiratory.

In the 2014 Forbes Global 2000 ranking, Actavis ranked 858th, a result that not only demonstrates its leading position in the pharmaceutical industry, but also reflects its positive contribution to global economic development. Through unremitting efforts and continuous innovation, Actavis is changing the landscape of the global healthcare industry.

Development History: From Regional Pharmaceutical Manufacturer to Global Leader

The history of Actavis Group can be traced back to 1956, when it was a regional pharmaceutical company focusing on the European market. With the changes in market demand and the advancement of technology, Actavis gradually turned its attention to the broader international market and rapidly expanded its business through a series of strategic mergers and acquisitions and cooperation.

From the end of the 20th century to the beginning of the 21st century, Actavis began to implement its globalization strategy and gradually acquired a number of well-known European and American pharmaceutical companies, including Watson Pharmaceuticals. This series of mergers and acquisitions not only enhanced Actavis' product portfolio, but also brought it advanced technology and management experience, significantly improving the company's competitiveness worldwide.

After entering the 21st century, Actavis further increased its R&D investment, especially in the fields of generic drugs and biosimilars. These achievements have helped Actavis occupy an important position in the global generic drug market and enable it to better meet the diverse needs of patients in different regions.

In recent years, Actavis has continued to deepen its internationalization process, continuously optimize its supply chain system, and improve production efficiency and service quality. At the same time, the company has also actively participated in social responsibility projects, worked hard to improve global public health conditions, and demonstrated its responsibility and passion as a responsible enterprise.

Core business: Diversified product portfolio to promote a healthy future

Actavis Group's core businesses cover a number of key therapeutic areas, including central nervous system diseases, digestive system diseases, cardiovascular diseases, metabolic diseases, anti-infective drugs, and respiratory diseases. With its rich experience and expertise, Actavis has developed a series of highly effective and safe drugs, providing reliable treatment options for millions of patients around the world.

• Central nervous system diseases: In this area, Actavis has launched a variety of drugs for the treatment of depression, anxiety, insomnia and other mental disorders, helping patients regain their physical and mental health.
• Digestive Disorders: From gastrointestinal issues to liver disease, Actavis offers medicines that can effectively relieve symptoms and promote recovery.
• Cardiovascular disease: Actavis has developed a number of drugs with significant therapeutic effects to treat common cardiovascular diseases such as hypertension and coronary heart disease, reducing patients' risk of disease.
• Metabolic diseases: In the management of diabetes and its complications, Actavis has launched a series of innovative therapies to help patients achieve a better quality of life.
• Anti-infective drugs: In the face of bacterial, viral and fungal infections, the antibiotics and antiviral drugs provided by Actavis play an important role.
• Respiratory diseases: Actavis has developed a variety of treatment options for respiratory diseases such as asthma and chronic obstructive pulmonary disease, alleviating patients' pain.

In addition to traditional chemical drugs, Actavis has also invested heavily in the field of biosimilars, striving to provide patients with more diverse treatment options. In addition, the company also focuses on the innovation of drug dosage forms, such as sustained-release tablets and injections, to improve the convenience and compliance of medication.

Technological innovation: the core driving force for development

Technological innovation has always been the core driving force of Actavis' development. In order to maintain its leading edge in the industry, Actavis invests huge amounts of money in R&D activities every year and has established a network of R&D centers around the world. These R&D centers bring together many top scientists and engineers who focus on new drug discovery, process optimization, quality control and other aspects.

In terms of new drug research and development, Actavis has adopted advanced computer-aided design technology, combined with big data analysis methods, to significantly improve the efficiency of drug screening. At the same time, the company has also carried out extensive cooperation with universities, research institutions and peer companies to jointly overcome technical difficulties and promote the overall progress of the industry.

For existing products, Actavis reduces costs and increases production by continuously improving production processes, thereby bringing benefits to more patients. For example, the introduction of continuous manufacturing technology in the production of solid oral dosage forms not only reduces energy consumption and waste emissions, but also improves product quality consistency.

In addition, Actavis also attaches great importance to digital transformation, using emerging technologies such as the Internet of Things and artificial intelligence to transform traditional business processes and realize functions such as visual supply chain management and precision marketing. These measures not only improve operational efficiency, but also create greater value for customers.

Global layout: serving every corner of the world

As a truly multinational company, Actavis has established numerous branches and production bases around the world, forming a complete sales and service network. Whether in developed economies or emerging market countries, Actavis can formulate corresponding market strategies based on local conditions to ensure that products can quickly reach target users.

In developed countries, Actavis promotes its products mainly by establishing long-term partnerships with hospitals, pharmacies and insurance companies. At the same time, the company also actively participates in various academic exchange activities to convey the latest research results to doctors and pharmacists and enhance brand influence.

In developing countries and regions, Actavis pays more attention to affordability and accessibility. It reduces drug prices by simplifying packaging and adjusting dosage, so that ordinary families can afford essential drugs; and improves the diagnosis and treatment level and medical service conditions by training grassroots medical staff.

It is worth mentioning that Actavis has also actively responded to the United Nations Sustainable Development Goals (SDGs) and participated in a number of public welfare projects aimed at eliminating health inequalities and promoting universal health coverage. For example, actions such as supporting the African malaria prevention and control program and donating children's vaccines all reflect Actavis' sense of responsibility and mission to the society.

Future Outlook: Continue to Lead the Industry Development Trend

Looking ahead, Actavis will continue to adhere to the innovation-driven development strategy, increase R&D investment, and explore more possible applications of cutting-edge technologies in the pharmaceutical field. At the same time, the company will closely monitor changes in global healthcare trends, adjust its business direction in a timely manner, and seize new growth opportunities.

In terms of market expansion, Actavis will further deepen its global layout, especially in fast-growing emerging markets such as Asia and Latin America, increase resource investment, and improve localized operation systems. In addition, the company will strengthen strategic cooperation with other pharmaceutical companies to jointly build an open and win-win ecosystem.

In the face of increasingly severe environmental challenges, Actavis is committed to taking more proactive measures to reduce carbon footprint, promote green production methods and protect natural resources. This is not only responsible for the earth, but also a guarantee for the healthy life of future generations.

In short, Actavis Group is marching towards a more brilliant future with firm steps. We believe that with the joint efforts of all employees, Actavis will become one of the most dynamic and creative companies in the global pharmaceutical industry and make greater contributions to the cause of human health.

Official website link:

www.actavis.com